A Phase 1 interventional study of Lasmiditan and Lasmiditan in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in Germany. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-31.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study was to determine how two doses of lasmiditan affected the heart in healthy participants. The study also evaluated how much lasmiditan got into the blood stream and how long it took the body to get rid of it. Information about side effects was collected. The study lasted a maximum of 46 days for each participant, not including screening.
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 155 are open to participants now.
Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
In good physical and mental health as determined by the following:
Exclusion Criteria:
Any of the following cardiac abnormalities on safety screening :
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single, PO dose of 100 mg lasmiditan administered on Day 1 in one of four treatment periods.
Drug: Lasmiditan
A single, PO dose of 400 mg lasmiditan administered on Day 1 in one of four treatment periods.
Drug: Lasmiditan
Placebo for lasmiditan and placebo for moxifloxacin administered on Day 1 in one of four treatment periods.
Drug: Placebo
A single, PO dose of moxifloxacin administered on Day 1 in one of four treatment periods.
Drug: Moxifloxacin
100 mg administered orally (PO)
Also known as: LY573144
400 mg administered PO
Also known as: LY573144
Placebo administered for lasmiditan or moxifloxacin
400 mg moxifloxacin administered PO
Change From Time Matched Baseline in Mean Fridericia-Corrected QT (QTcF) Values of Lasmiditan and Moxifloxacin
The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTcF = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and R-R wave (RR), which is the interval between two R waves. PR is the interval between the P wave and the ventricular depolarization wave (QRS) complex.
Time frame: Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose
Change From Time Matched Baseline in Mean Individually-Corrected QT (QTcI) Values of Lasmiditan and Moxifloxacin
The corrected QT interval, individualized (QTcI) is a measurement of the electrical impulses through the largest part of the heart muscle individualized for participant pre-dose values. A negative change is a shortening of the QTc interval, a positive change is a lengthening of the QTc interval.
Time frame: Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose
Change From Baseline in Mean Cardiac Intervals: RR Interval of Lasmiditan and Moxifloxacin
ECGs were used to calculate cardiac intervals. The RR interval is the time between two R waves.
Time frame: Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose
Change From Baseline in Mean Cardiac Intervals:QRS of Lasmiditan and Moxifloxacin
ECGs were used to calculate cardiac intervals. The QRS interval is the time the segment of the ECG that corresponds to depolarization of the ventricles.
Time frame: Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose
Change From Baseline in Mean Heart Rate (HR) of Lasmiditan and Moxifloxacin
Heart rate was determined during ambulatory blood pressure monitoring (ABPM).
Time frame: Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose
Number of Incidents in Electrocardiogram (ECG) Abnormalities in QTcF Interval Greater Than 450 Milliseconds
ECGs were assessed for morphology abnormalities or changes in QTcf interval greater than 450 milliseconds by a board-certified cardiologist
Time frame: Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Lasmiditan
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Lasmiditan.
Time frame: Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose
Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC-t) of Lasmiditan
Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC-t) of Lasmiditan.
Time frame: Day 1: Predose, 30 minutes postdose, 1 hour (hr), 1.5 hr, 2 hr, 2.5 hr, 3 hr, 3.5 hr, 4 hr, 6 hr, 8, hr, 12 hr and 24 hr postdose
| Milestone | Sequence 1 ABDC | Sequence 2 BCAD | Sequence 3 CDBA | Sequence 4 DACB |
|---|---|---|---|---|
| Started | 14 | 14 | 14 | 14 |
| Received at least 1 dose of study drug | 14 | 14 | 14 | 14 |
| Completed | 14 | 14 | 13 | 14 |
| Not completed | 0 | 0 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 |
| Milestone | Sequence 1 ABDC | Sequence 2 BCAD | Sequence 3 CDBA | Sequence 4 DACB |
|---|---|---|---|---|
| Started | 14 | 14 | 13 | 14 |
| Received at least 1 dose of study drug | 14 | 13 | 13 | 14 |
| Completed | 14 | 13 | 13 | 14 |
| Not completed | 0 | 1 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 |
| Milestone | Sequence 1 ABDC | Sequence 2 BCAD | Sequence 3 CDBA | Sequence 4 DACB |
|---|---|---|---|---|
| Started | 14 | 13 | 13 | 14 |
| Received at least one dose of study drug | 13 | 12 | 13 | 14 |
| Completed | 13 | 12 | 13 | 14 |
| Not completed | 1 | 1 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 1 | 0 | 0 |
| Milestone | Sequence 1 ABDC | Sequence 2 BCAD | Sequence 3 CDBA | Sequence 4 DACB |
|---|---|---|---|---|
| Started | 13 | 12 | 13 | 14 |
| Received at least 1 dose of study drug | 13 | 12 | 13 | 14 |
| Completed | 13 | 12 | 12 | 14 |
| Not completed | 0 | 0 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 0 |
The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTcF = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and R-R wave (RR), which is the interval between two R waves. PR is the interval between the P wave and the ventricular depolarization wave (QRS) complex.
| milliseconds | 100 mg Lasmiditan | 400 mg Lasmiditan | Placebo | Moxifloxacin |
|---|---|---|---|---|
| 30 minutes postdose | -8.90 ± 7.20 | -9.27 ± 6.29 | -5.49 ± 5.52 | 1.90 ± 8.69 |
| 1 hour postdose | -7.42 ± 5.83 | -4.58 ± 8.13 | -3.94 ± 5.15 | 8.36 ± 6.51 |
| 1.5 hours postdose | -7.63 ± 5.98 | -3.07 ± 7.91 | -3.68 ± 4.66 | 7.63 ± 6.32 |
| 2 hours postdose | -6.96 ± 7.08 | -1.12 ± 8.10 | -3.83 ± 5.28 | 8.16 ± 7.21 |
| 2.5 hours postdose | -5.26 ± 7.36 | 0.15 ± 8.67 | -2.89 ± 4.99 | 8.12 ± 7.15 |
| 3 hours postdose | -2.81 ± 6.95 | 2.06 ± 8.18 | -2.04 ± 5.71 | 10.01 ± 6.42 |
| 3.5 hours postdose | -2.39 ± 7.63 | 3.58 ± 6.88 | -1.85 ± 4.59 | 10.37 ± 7.09 |
| 4 hours postdose | -2.12 ± 6.89 | 4.77 ± 7.49 | -2.34 ± 5.65 | 9.39 ± 5.85 |
| 6 hours postdose | -4.33 ± 7.32 | -0.18 ± 7.38 | -3.39 ± 6.59 | 4.91 ± 7.05 |
| 8 hours postdose | -6.74 ± 7.16 | -1.84 ± 7.82 | -3.99 ± 7.11 | 3.90 ± 7.13 |
| 12 hours postdose | -3.73 ± 5.72 | -0.41 ± 6.99 | -1.79 ± 5.91 | 4.63 ± 7.12 |
| 24 hours postdose | 0.74 ± 7.51 | 0.38 ± 7.06 | 0.45 ± 6.18 | 6.61 ± 7.91 |
The corrected QT interval, individualized (QTcI) is a measurement of the electrical impulses through the largest part of the heart muscle individualized for participant pre-dose values. A negative change is a shortening of the QTc interval, a positive change is a lengthening of the QTc interval.
| milliseconds | 100 mg Lasmiditan | 400 mg Lasmiditan | Placebo | Moxifloxacin |
|---|---|---|---|---|
| 30 minutes postdose | -9.92 ± 7.62 | -10.56 ± 8.00 | -5.27 ± 6.04 | 2.24 ± 8.88 |
| 1 hour postdose | -9.50 ± 7.74 | -6.90 ± 8.98 | -3.35 ± 5.52 | 8.96 ± 7.14 |
| 1.5 hours postdose | -9.39 ± 6.93 | -4.73 ± 8.29 | -2.81 ± 5.58 | 8.61 ± 6.42 |
| 2 hours postdose | -8.74 ± 8.34 | -2.65 ± 8.56 | -3.49 ± 5.82 | 8.29 ± 7.03 |
| 2.5 hours postdose | -7.90 ± 9.42 | -1.80 ± 8.84 | -2.44 ± 5.61 | 8.40 ± 7.53 |
| 3 hours postdose | -5.08 ± 8.29 | -0.13 ± 8.63 | -1.70 ± 6.10 | 11.01 ± 6.89 |
| 3.5 hours postdose | -3.86 ± 8.72 | 1.90 ± 7.48 | -1.67 ± 5.01 | 11.43 ± 7.38 |
| 4 hours postdose | -3.25 ± 8.07 | 3.27 ± 8.44 | -1.19 ± 6.37 | 10.28 ± 6.50 |
| 6 hours postdose | -4.84 ± 7.00 | -1.27 ± 6.65 | -3.13 ± 6.61 | 4.85 ± 7.37 |
| 8 hours postdose | -7.10 ± 7.76 | -3.08 ± 8.23 | -3.89 ± 6.77 | 4.04 ± 7.01 |
| 12 hours postdose | -4.08 ± 5.88 | -0.64 ± 6.86 | -1.65 ± 6.09 | 4.87 ± 7.14 |
| 24 hours postdose | 1.60 ± 6.84 | 0.45 ± 6.85 | 0.81 ± 6.22 | 6.74 ± 8.14 |
ECGs were used to calculate cardiac intervals. The RR interval is the time between two R waves.
| milliseconds | 100 mg Lasmiditan | 400 mg Lasmiditan | Placebo | Moxifloxacin |
|---|---|---|---|---|
| 30 minutes postdose | 74.40 ± 76.26 | 98.52 ± 72.99 | 42.13 ± 56.00 | 18.66 ± 61.84 |
| 1 hour postdose | 149.22 ± 77.73 | 153.15 ± 65.13 | 49.87 ± 62.40 | 9.63 ± 63.32 |
| 1.5 hours postdose | 143.29 ± 80.63 | 130.79 ± 55.91 | 36.84 ± 66.52 | 13.44 ± 61.66 |
| 2 hours postdose | 118.39 ± 60.84 | 128.10 ± 48.50 | 44.69 ± 53.70 | 26.01 ± 54.44 |
| 2.5 hours postdose | 117.90 ± 73.85 | 132.86 ± 54.35 | 29.28 ± 51.39 | 26.90 ± 68.18 |
| 3 hours postdose | 105.56 ± 63.82 | 119.52 ± 60.66 | 30.84 ± 57.28 | 24.87 ± 66.41 |
| 3.5 hours postdose | 89.85 ± 56.54 | 101.86 ± 59.04 | 36.77 ± 50.34 | 19.01 ± 65.56 |
| 4 hours postdose | 72.22 ± 57.19 | 83.00 ± 56.84 | 30.32 ± 51.11 | 13.64 ± 68.55 |
| 6 hours postdose | -26.01 ± 69.03 | -3.07 ± 63.34 | -88.95 ± 60.15 | -84.12 ± 63.34 |
| 8 hours postdose | 5.63 ± 73.58 | 29.01 ± 66.89 | -50.89 ± 75.72 | -49.70 ± 52.21 |
| 12 hours postdose | -26.70 ± 77.94 | 5.19 ± 73.16 | -61.53 ± 76.51 | -74.80 ± 70.71 |
| 24 hours postdose | -16.37 ± 68.00 | -5.64 ± 63.34 | -11.66 ± 60.48 | -13.02 ± 52.97 |
ECGs were used to calculate cardiac intervals. The QRS interval is the time the segment of the ECG that corresponds to depolarization of the ventricles.
| milliseconds | 100 mg Lasmiditan | 400 mg Lasmiditan | Placebo | Moxifloxacin |
|---|---|---|---|---|
| 30 minutes postdose | 0.11 ± 1.12 | -0.10 ± 1.23 | 0.09 ± 1.28 | -0.00 ± 0.97 |
| 1 hours postdose | -0.24 ± 1.21 | 0.45 ± 1.35 | -0.02 ± 1.20 | -0.12 ± 1.07 |
| 1.5 hours postdose | -0.48 ± 1.13 | 0.19 ± 1.24 | -0.37 ± 1.06 | -0.12 ± 1.09 |
| 2 hours postdose | -0.73 ± 1.12 | 0.10 ± 1.08 | -0.30 ± 1.22 | -0.29 ± 1.14 |
| 2.5 hours postdose | -0.75 ± 1.41 | 0.30 ± 1.22 | -0.21 ± 1.08 | -0.20 ± 1.11 |
| 3 hours postdose | -0.63 ± 1.21 | 0.08 ± 1.19 | -0.26 ± 1.19 | -0.35 ± 0.93 |
| 3.5 hours postdose | -0.58 ± 1.00 | 0.15 ± 1.15 | -0.17 ± 0.98 | -0.57 ± 1.34 |
| 4 hours postdose | -0.54 ± 1.03 | 0.29 ± 1.17 | -0.20 ± 0.95 | -0.58 ± 1.25 |
| 6 hours postdose | 0.20 ± 1.43 | 0.64 ± 1.50 | 0.73 ± 1.34 | 0.13 ± 1.39 |
| 8 hours postdose | -0.41 ± 1.36 | -0.39 ± 1.43 | -0.28 ± 1.38 | -0.67 ± 1.34 |
| 12 hours postdose | 0.34 ± 1.46 | 0.24 ± 1.67 | 0.63 ± 1.05 | 0.32 ± 1.52 |
| 24 hours postdose | 0.33 ± 1.22 | -0.07 ± 1.22 | -0.10 ± 1.32 | 0.09 ± 1.28 |
Heart rate was determined during ambulatory blood pressure monitoring (ABPM).
| beats per minute | 100 mg Lasmiditan | 400 mg Lasmiditan | Placebo | Moxifloxacin |
|---|---|---|---|---|
| 30 minutes postdose | -3.90 ± 5.05 | -5.51 ± 3.74 | -2.41 ± 3.22 | -1.02 ± 3.75 |
| 1 hour postdose | -7.82 ± 3.95 | -8.40 ± 3.21 | -2.77 ± 3.55 | -0.42 ± 4.05 |
| 1.5 hours postdose | -7.55 ± 4.16 | -7.41 ± 3.14 | -2.01 ± 3.53 | -0.67 ± 3.73 |
| 2 hours postdose | -6.62 ± 3.22 | -7.30 ± 2.93 | -2.65 ± 3.17 | -1.52 ± 3.19 |
| 2.5 hours postdose | -6.49 ± 4.07 | -7.59 ± 3.27 | -1.75 ± 2.97 | -1.48 ± 4.07 |
| 3 hours postdose | -5.96 ± 3.32 | -6.82 ± 3.53 | -1.83 ± 3.35 | -1.26 ± 3.95 |
| 3.5 hours postdose | -5.26 ± 3.02 | -6.02 ± 3.50 | -2.32 ± 3.06 | -0.91 ± 4.23 |
| 4 hours postdose | -4.22 ± 3.06 | -5.02 ± 3.42 | -1.82 ± 3.19 | -0.55 ± 4.37 |
| 6 hours postdose | 1.65 ± 4.52 | -0.10 ± 3.77 | 6.29 ± 5.18 | 5.84 ± 4.84 |
| 8 hours postdose | -0.43 ± 4.73 | -1.96 ± 3.93 | 3.42 ± 5.05 | 3.10 ± 3.42 |
| 12 hours postdose | 1.58 ± 5.31 | -0.50 ± 4.66 | 4.17 ± 5.46 | 4.95 ± 5.12 |
| 24 hours postdose | 1.01 ± 4.45 | 0.42 ± 4.09 | 0.89 ± 3.96 | 0.81 ± 3.60 |
ECGs were assessed for morphology abnormalities or changes in QTcf interval greater than 450 milliseconds by a board-certified cardiologist
| Incidents | 100 mg Lasmiditan | 400 mg Lasmiditan | Placebo | Moxifloxacin |
|---|---|---|---|---|
| Predose | 0 | 0 | 0 | 0 |
| 30 minutes postdose | 0 | 0 | 0 | 1 |
| 1 hour postdose | 2 | 0 | 0 | 2 |
| 1.5 hours postdose | 0 | 1 | 0 | 2 |
| 2 hours postdose | 1 | 1 | 0 | 3 |
| 2.5 hours postdose | 1 | 1 | 0 | 2 |
| 3 hours postdose | 1 | 1 | 0 | 2 |
| 3.5 hours postdose | 1 | 2 | 0 | 3 |
| 4 hours postdose | 1 | 1 | 0 | 3 |
| 6 hours postdose | 0 | 0 | 0 | 0 |
| 8 hours postdose | 0 | 1 | 0 | 0 |
| 12 hours postdose | 0 | 0 | 0 | 0 |
| 24 hours postdose | 0 | 0 | 0 | 0 |
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Lasmiditan.
| nanogram per milliliter | 100 mg Lasmiditan | 400 mg Lasmiditan |
|---|---|---|
| Pharmacokinetics (PK): Maximum Concentration (Cmax) of Lasmiditan | 104.55 ± 41.452 | 526.15 ± 240.997 |
Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC-t) of Lasmiditan.
| hours*nanogram per milliliter | 100 mg Lasmiditan | 400 mg Lasmiditan |
|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC-t) of Lasmiditan | 684.66 ± 278.258 | 3189.08 ± 1152.338 |
Collected over 75 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 100 mg Lasmiditan | 0/52 (0%) | 0/52 (0%) | 21/52 (40.4%) |
| 400 mg Lasmiditan | 0/55 (0%) | 0/55 (0%) | 33/55 (60%) |
| Placebo | 0/54 (0%) | 0/54 (0%) | 7/54 (13%) |
| Moxifloxacin | 0/52 (0%) | 1/52 (1.9%) | 9/52 (17.3%) |
| Event | 100 mg Lasmiditan | 400 mg Lasmiditan | Placebo | Moxifloxacin |
|---|---|---|---|---|
| Pilonidal cystInfections and infestations | 0/52 | 0/55 | 0/54 | 1/52 |
| Event | 100 mg Lasmiditan | 400 mg Lasmiditan | Placebo | Moxifloxacin |
|---|---|---|---|---|
| DizzinessNervous system disorders | 14/52 | 23/55 | 3/54 | 0/52 |
| SomnolenceNervous system disorders | 13/52 | 22/55 | 3/54 | 4/52 |
| ParaesthesiaNervous system disorders | 5/52 | 8/55 | 0/54 | 0/52 |
| NauseaGastrointestinal disorders | 4/52 | 2/55 | 0/54 | 4/52 |
| AstheniaGeneral disorders | 0/52 | 4/55 | 0/54 | 0/52 |
| NasopharyngitisInfections and infestations | 1/52 | 2/55 | 2/54 | 3/52 |
| DiscomfortGeneral disorders | 0/52 | 3/55 | 0/54 | 0/52 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 0/52 | 3/55 | 0/54 | 0/52 |
| DysarthriaNervous system disorders | 0/52 | 3/55 | 0/54 | 0/52 |
| Restless legs syndromeNervous system disorders | 0/52 | 3/55 | 0/54 | 0/52 |
All randomized participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Sequence 1 ABDC | Sequence 2 BCAD | Sequence 3 CDBA | Sequence 4 DACB | Total |
|---|---|---|---|---|---|
| Mean | 40.6 ± 12.3 | 38.4 ± 11.7 | 37.5 ± 10.8 | 40.7 ± 9.1 | 39.3 ± 10.8 |
| Sex: Female, Male(Participants) | Sequence 1 ABDC | Sequence 2 BCAD | Sequence 3 CDBA | Sequence 4 DACB | Total |
|---|---|---|---|---|---|
| Female | 9 | 7 | 5 | 6 | 27 |
| Male | 5 | 7 | 9 | 8 | 29 |
| Ethnicity (NIH/OMB)(Participants) | Sequence 1 ABDC | Sequence 2 BCAD | Sequence 3 CDBA | Sequence 4 DACB | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 14 | 14 | 14 | 14 | 56 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Sequence 1 ABDC | Sequence 2 BCAD | Sequence 3 CDBA | Sequence 4 DACB | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 0 | 0 | 1 |
| White | 13 | 13 | 14 | 13 | 53 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 | 2 |
| Region of Enrollment(Participants) | Sequence 1 ABDC | Sequence 2 BCAD | Sequence 3 CDBA | Sequence 4 DACB | Total |
|---|---|---|---|---|---|
| Germany | 14 | 14 | 14 | 14 | 56 |
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Ran from Sep 2011 to primary completion in Dec 2011, 3 months.
Results were first posted in Jan 2020, 8 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lasmiditan